Clinical Trial

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-25; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT06617182
Lead Sponsor Yongquan Shi
Conditions Radiation Enteritis
Enrollment 150 participants
Start Date 2024-09-30
Primary Completion 2028-10-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27